Real-world experience with the pentaspline pulsed field ablation system: one-year outcomes of the FARADISE registry
Europace · 01.09.2025 · 27 (9)
DOI: 10.1093/europace/euaf182 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Europace, online erschienen am 01.09.2025. Verfasst von Lucas V A Boersma und 26 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, St. Antonius Hospital, PO 2500, 3430 EM, Nieuwegein, The Netherlands. Hauptthemen laut MEDLINE: Atrial Fibrillation, Cardiac Catheters, Catheter Ablation, Pulmonary Veins. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boston Scientific.
Abstract (Originalsprache)
Aims
Clinical studies with protocol-mandated workflow and monitoring have analysed performance of pulsed field ablation (PFA) for treating atrial fibrillation (AF). The FARADISE registry captures global use of the pentaspline PFA catheter in real-world clinical practice with a follow-up of 3 years. Methods and results FARADISE is a prospective, non-randomized, multi-national registry (NCT05501873) that enrolled subjects clinically indicated for ablation using the pentaspline PFA catheter per medical judgement and hospital standard-of-care. Procedural characteristics, safety, and clinical effectiveness up to 12-months were collected. In total, 1158 AF patients received PFA across 48 centres in 21 countries (64 ± 11 years, 33% female, 90% de novo, 65% paroxysmal AF). Pulmonary vein isolation (PVI)-only procedures were performed in 80.8% of paroxysmal vs. 57.5% for non-paroxysmal patients (P < 0.01). Median procedure, left atrial dwell, and fluoroscopy times were 51[40–70], 31[24–41], and 12[8–17] min, respectively. The rate of early onset serious adverse events was 1.5% and did not differ by ablation strategy or AF indication. At 1-year, clinical effectiveness was 80.8% for paroxysmal AF and 67.7% for non-paroxysmal AF, with no difference within indication by lesion set (paroxysmal: 81.2% PVI-only vs. 79.0% PVI+, P = 0.65; non-paroxysmal: 67.5% PVI-only vs. 67.7% PVI+, P = 0.79). Acute results reinforce a short procedural learning curve with no difference in 1-year effectiveness by operator experience.
Conclusion
The FARADISE registry provides a snapshot of real-world clinical use of the pentaspline PFA catheter. Acute results demonstrate favourable procedural and safety outcomes regardless of AF indication. One-year outcomes are encouraging, with no differences seen within indication based on ablation strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiology Department, St. Antonius Hospital, PO 2500, 3430 EM, Nieuwegein, The Netherlands.
- Mater Private Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland.
- Biomedical Science and Public Health Department, Polytechnic University of Marche, AOUM Hospital, Ancona, Italy.
- University Clinic of Navarra, Navarra, Spain.
- Onassis Cardiac Surgery Center, Kallithea, Greece.
- Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
ORCID-Profile: Lucas V A Boersma, Gábor Széplaki, Antonio Dello Russo, Ignacio García-Bolao, Nándor Szegedi, Stephan Willems, Haris Haqqani, Estelle Gandjbakhch, Francesco Solimene, George Andrikopoulos, Pascal Defaye, Armin Luik, Patrick Lugenbiel, Lars Eckardt, Alexandre Ouss, Jean-Manuel Herzet, Joaquín Osca, Madeline Johnson, Johan Vijgen
Förderung
- Boston Scientific
Zitieren
APA
Boersma, L. V. A., Széplaki, G., Dello Russo, A., García-Bolao, I., Efremidis, M., Szegedi, N., Willems, S., Haqqani, H., Gandjbakhch, E., Solimene, F., Andrikopoulos, G., Fiala, M., Defaye, P., Luik, A., Lugenbiel, P., Eckardt, L., Ouss, A., Herzet, J. M., Maqueda, J. R., …, & Vijgen, J. (2025). Real-world experience with the pentaspline pulsed field ablation system: one-year outcomes of the FARADISE registry. Europace, 27(9). https://doi.org/10.1093/europace/euaf182
Vancouver
Boersma LVA, Széplaki G, Dello Russo A, García-Bolao I, Efremidis M, Szegedi N, et al. Real-world experience with the pentaspline pulsed field ablation system: one-year outcomes of the FARADISE registry. Europace. 2025;27(9). doi:10.1093/europace/euaf182
BibTeX
@article{Boersma2025,
author = {Boersma, Lucas V A and Széplaki, Gábor and Dello Russo, Antonio and García-Bolao, Ignacio and Efremidis, Michael and Szegedi, Nándor and Willems, Stephan and Haqqani, Haris and Gandjbakhch, Estelle and Solimene, Francesco and Andrikopoulos, George and Fiala, Martin and Defaye, Pascal and Luik, Armin and Lugenbiel, Patrick and Eckardt, Lars and Ouss, Alexandre and Herzet, Jean-Manuel and Maqueda, Javier Ramos and Abbey, Sélim and Osca, Joaquín and Hussin, Azlan and Cielen, Nele and Johnson, Madeline and Albrecht, Elizabeth M and Sutton, Brad S and Vijgen, Johan},
title = {Real-world experience with the pentaspline pulsed field ablation system: one-year outcomes of the FARADISE registry},
journal = {Europace},
year = {2025},
volume = {27},
number = {9},
doi = {10.1093/europace/euaf182}
}
EUVIMED